Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1993 Jan;48(1):68–69. doi: 10.1136/thx.48.1.68

Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study.

C Agustí 1, A Xaubet 1, E Ballester 1, A Alarcón 1, C Picado 1
PMCID: PMC464249  PMID: 8434357

Abstract

BACKGROUND: A report has recently been published concerning a patient with a cryptogenic fibrosing alveolitis who showed a striking improvement after being treated with the antiviral drug ribavirin (tribavirin, Virazid). The objective of this study was to further evaluate, in an open trial, the efficacy of rivabirin in cryptogenic fibrosing alveolitis. METHODS: Ten patients (eight women) with advanced cryptogenic fibrosing alveolitis received aerosolised ribavirin (6 g/day for 15 days). Chest radiographs, lung function, and severity of dyspnoea were evaluated before and after two weeks of rivabirin treatment and also at three and 12 months. RESULTS: No differences in radiographs, lung function impairment, or severity of dyspnoea were found after treatment. No side effects were detected. CONCLUSIONS: Administration of high doses of aerosolised ribavirin has no beneficial effects in patients with advanced cryptogenic fibrosing alveolitis.

Full text

PDF
69

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alton E. W., Johnson M., Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med. 1989 Jul;83(4):277–279. doi: 10.1016/s0954-6111(89)80196-9. [DOI] [PubMed] [Google Scholar]
  2. Cherniack R. M., Crystal R. G., Kalica A. R. NHLBI Workshop summary. Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Respir Dis. 1991 Mar;143(3):680–683. doi: 10.1164/ajrccm/143.3.680. [DOI] [PubMed] [Google Scholar]
  3. Han L. Y., Wilson R., Slater S., Rutman A., Read R. C., Snell N. J., Cole P. J. In vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax. 1990 Feb;45(2):100–104. doi: 10.1136/thx.45.2.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Haslam P. L. Cryptogenic fibrosing alveolitis: pathogenetic mechanisms and therapeutic approaches. Eur Respir J. 1990 Mar;3(3):355–357. [PubMed] [Google Scholar]
  5. Haslam P. L. Cryptogenic fibrosing alveolitis: pathogenetic mechanisms and therapeutic approaches. Eur Respir J. 1990 Mar;3(3):355–357. [PubMed] [Google Scholar]
  6. Johnson M. A., Kwan S., Snell N. J., Nunn A. J., Darbyshire J. H., Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax. 1989 Apr;44(4):280–288. doi: 10.1136/thx.44.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Prieto J., Sangro B., Beloqui O. Ribavirin in desquamative interstitial pneumonia. Chest. 1988 Feb;93(2):446–447. doi: 10.1378/chest.93.2.446b. [DOI] [PubMed] [Google Scholar]
  8. Raghu G., Depaso W. J., Cain K., Hammar S. P., Wetzel C. E., Dreis D. F., Hutchinson J., Pardee N. E., Winterbauer R. H. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991 Aug;144(2):291–296. doi: 10.1164/ajrccm/144.2.291. [DOI] [PubMed] [Google Scholar]
  9. Roca J., Rodriguez-Roisin R., Cobo E., Burgos F., Perez J., Clausen J. L. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):1026–1032. doi: 10.1164/ajrccm/141.4_Pt_1.1026. [DOI] [PubMed] [Google Scholar]
  10. Roca J., Sanchis J., Agusti-Vidal A., Segarra F., Navajas D., Rodriguez-Roisin R., Casan P., Sans S. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir. 1986 May-Jun;22(3):217–224. [PubMed] [Google Scholar]
  11. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980 Mar;35(3):171–180. doi: 10.1136/thx.35.3.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Xaubet A., Rodriguez-Roisín R., Bombí J. A., Marín A., Roca J., Agustí-Vidal A. Correlation of bronchoalveolar lavage and clinical and functional findings in asbestosis. Am Rev Respir Dis. 1986 May;133(5):848–854. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES